Apellis achieved a dramatic turnaround from significant losses to profitability with $22.4M net income, while expanding their approved indications for EMPAVELI to include C3G and primary IC-MPGN in addition to PNH.
This represents a fundamental inflection point for Apellis as they transition from a loss-making biotech to a profitable commercial-stage pharmaceutical company. The expanded EMPAVELI approvals significantly broaden their addressable market beyond just PNH, providing multiple revenue drivers for sustained growth.
Apellis delivered exceptional financial performance with revenue growing 28.5% to $1.0B while achieving positive operating income of $55.4M (vs. -$165.0M loss) and net income of $22.4M (vs. -$197.9M loss), representing a complete turnaround to profitability. Operating cash flow swung dramatically positive to $45.3M from -$87.9M, while the balance sheet strengthened significantly with stockholders' equity increasing 62% to $370.1M and inventory growing 75% to support expanded commercial operations. The substantial increases in accounts receivable (+38.2%) and current assets (+28.6%) reflect the robust revenue growth and working capital needs of a rapidly scaling commercial business.
Operating cash flow surged 151.6% — exceptional cash generation, highest quality earnings signal.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Net income grew 111.3% — bottom-line growth signals improving overall business health.
Inventory surged 75.1% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Current liabilities surged 74.4% — significant near-term obligations; verify ability to meet short-term debt.
Equity base grew 62% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Receivables surged 38.2% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Current assets grew 28.6% — improving short-term liquidity or inventory/receivables build.
Revenue growing 28.5% — solid top-line momentum, watch margins for quality of growth.
Capex reduced 22.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →